Analysis of NK cell activity, lymphocyte reactivity to mitogens and serotest PSA and TPS values in patients with primary and disseminated prostate cancer, PIN and BPH

Anticancer Research

Volumn 17, Issue 3 B, 1997, Pages 1671-1675

  Kaštelan, Maja ^a   Kovačić, Ksenija ^a   Tarle, Robert ^a   Kraljić, Ivo ^a   Tarle, Marko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Mitogenes con A; MWP; NK activity; PHA; Prostate cancer; Serum PSA and TPS

Indexed keywords

CD16 ANTIGEN; CONCANAVALIN A; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL ACTIVITY; CELL DEATH; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; STROMA CELL; T LYMPHOCYTE; TUMOR DIFFERENTIATION;

AGED; ANTIGENS, CD; B-LYMPHOCYTES; HUMANS; KILLER CELLS, NATURAL; LECTINS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, IGG; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 1842326805     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Lahat N, Alexander N, Levin DR and Moskowitz B: The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate. Cancer Immunol Immunother 28: 208-213, 1989.
2. Santori A, Palmieri G, Procopio A et al: Mechanism of target cell killing by natural killer cells. Ital J Med 4: 59-66, 1989.
3. Moody DB, Robinson JC, Ewing CM, Lazenby AJ and Isaacs WB: Interleukin-2 transacted prostate cancer cells generate a local antitumor effet in vivo. Prostate 24: 244-251, 1994.
4. Tarle M, Kraljic I and Kastelan M: Comparison between NK cell activity and prostate cancer stage and grade in untreated patients: correlation with tumor markers and hormonal serotest data. Urol Res 21: 17-21, 1993.
5. Kastelan M, Kraljic I and Tarle M: NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: Hormone regulatory effects in vivo. Prostate 21: 111-120, 1992.
6. Oesterling JE: Prostate specific antigen. A critical assessment of the most useful marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
7. Tarle M: Serial measurement of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer. Anticancer Res 13: 769-778, 1993.
8. Hartzman RJ, Segall M, Bach ML and Bach FH: Histocompatibility matching. VI. Miniaturization of the mixed leukocyte cultures test. A preliminary report. Transplantation 11: 268-284, 1971.
9. Tarle M, Kovačić K and Alfirević-Strelkov A: Correlation between bone scans and serum osteocalcin, PSA and PAP in monitoring patients with disseminated cancer of the prostate. Prostate 15: 211-219, 1989.
10. Carter HB, Piantadosi M and Isaacs JT: Clinical evidence for and implication of the multistep development of prostate cancer. J Urol 143: 742-759, 1990.
11. Tarle M, Frković-Grazio S, Kraljić I and Kovačić K: A more objective staging of advanced prostate cancer-Routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA and NSE values. Prostate 24: 143-148, 1994.
12. Kraijić I and Tarle M: Serum TPS level as a probe for prostate cancer activity. PSA, PAP and TPS values in patient treated with cytotoxic agents. 13th Inter Conference on Human Tumor Markers, Singapore. June 1996. J Tumor Marker Oncology 11: 85-86, 1996.
13. Tarle M, Kovačić K and Kaštelan M: Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors. Anticancer Res 13: 215-218, 1993.
14. Stawarz B, Zielinski H, Szmigielski S, Rappaport E, Debicki P, Petrovich Z: Transrectal hyperthermia as palliative treatment for advanced adenocarcinoma of prostate and studies of cell-mediated immunity. Urology, 41: 548-553, 1993.
15. Schulze H, Berges R and Claus S: Proliferation and apoptosis in benign prostatic hyperplasia. Proc of the American Urological Association, Orlando, May 1996. J Urol 155: 346A, 1996.